NASDAQ:SPRO Spero Therapeutics (SPRO) Stock Price, News & Analysis $0.68 -0.01 (-2.05%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.68 +0.00 (+0.44%) As of 05/27/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Spero Therapeutics Stock (NASDAQ:SPRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Spero Therapeutics alerts:Sign Up Key Stats Today's Range$0.66▼$0.7050-Day Range$0.56▼$0.9052-Week Range$0.51▼$1.53Volume68,596 shsAverage Volume181,754 shsMarket Capitalization$38.13 millionP/E Ratio9.74Dividend YieldN/APrice Target$5.00Consensus RatingModerate Buy Company OverviewSpero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More… Spero Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreSPRO MarketRank™: Spero Therapeutics scored higher than 90% of companies evaluated by MarketBeat, and ranked 265th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingSpero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSpero Therapeutics has received no research coverage in the past 90 days.Read more about Spero Therapeutics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Spero Therapeutics are expected to grow in the coming year, from ($1.20) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spero Therapeutics is 9.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.73.Price to Earnings Ratio vs. SectorThe P/E ratio of Spero Therapeutics is 9.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.01.Price to Book Value per Share RatioSpero Therapeutics has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Spero Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.15% of the outstanding shares of Spero Therapeutics have been sold short.Short Interest Ratio / Days to CoverSpero Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Spero Therapeutics has recently decreased by 19.48%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldSpero Therapeutics does not currently pay a dividend.Dividend GrowthSpero Therapeutics does not have a long track record of dividend growth.Read more about Spero Therapeutics' dividend. Sustainability and ESG4.7 / 5Environmental Score-0.80 Percentage of Shares Shorted1.15% of the outstanding shares of Spero Therapeutics have been sold short.Short Interest Ratio / Days to CoverSpero Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Spero Therapeutics has recently decreased by 19.48%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News SentimentN/A News SentimentSpero Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Spero Therapeutics this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Spero Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.52% of the stock of Spero Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 25.60% of the stock of Spero Therapeutics is held by institutions.Read more about Spero Therapeutics' insider trading history. Receive SPRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRO Stock News HeadlinesSpero Therapeutics (NASDAQ:SPRO) & Perrigo (NYSE:PRGO) Head to Head AnalysisMay 19, 2025 | americanbankingnews.comSpero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business UpdateMay 13, 2025 | globenewswire.comF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLaren Engineering, a NASDAQ-listed marine tech company unveiled a groundbreaking new electric powertrain set to transform the industry.May 28, 2025 | The Tomorrow Investor (Ad)Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025May 5, 2025 | globenewswire.comSpero Therapeutics, Inc.: Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive OfficerApril 29, 2025 | finanznachrichten.deSpero Therapeutics Appoints Esther Rajavelu as President and Chief Executive OfficerApril 28, 2025 | globenewswire.comSpero Therapeutics Analyst RatingsApril 7, 2025 | benzinga.comTD Cowen Sticks to Their Hold Rating for Spero Therapeutics (SPRO)April 2, 2025 | markets.businessinsider.comSee More Headlines SPRO Stock Analysis - Frequently Asked Questions How have SPRO shares performed this year? Spero Therapeutics' stock was trading at $1.03 at the beginning of 2025. Since then, SPRO shares have decreased by 33.8% and is now trading at $0.6820. View the best growth stocks for 2025 here. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics, Inc. (NASDAQ:SPRO) issued its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.30. The company earned $5.87 million during the quarter, compared to the consensus estimate of $11 million. Spero Therapeutics had a net margin of 3.30% and a trailing twelve-month return on equity of 4.03%. When did Spero Therapeutics IPO? Spero Therapeutics (SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Spero Therapeutics' major shareholders? Spero Therapeutics' top institutional shareholders include Anson Funds Management LP (13.66%), Acadian Asset Management LLC (1.56%), Mackenzie Financial Corp (0.37%) and Simplex Trading LLC. Insiders that own company stock include Aquilo Capital Management, Llc, Sath Shukla, Esther Rajavelu, Ankit Mahadevia, Kamal Hamed and Timothy Keutzer. View institutional ownership trends. How do I buy shares of Spero Therapeutics? Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spero Therapeutics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), NVIDIA (NVDA), Editas Medicine (EDIT) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/13/2025Today5/27/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SPRO CIK1701108 Websperotherapeutics.com Phone(857) 242-1600FaxN/AEmployees150Year Founded2013Price Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+633.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E Ratio9.74 Forward P/E RatioN/A P/E GrowthN/ANet Income$22.81 million Net Margins3.30% Pretax Margin3.39% Return on Equity4.03% Return on Assets2.21% Debt Debt-to-Equity RatioN/A Current Ratio2.68 Quick Ratio2.68 Sales & Book Value Annual Sales$28.30 million Price / Sales1.35 Cash Flow$0.42 per share Price / Cash Flow1.62 Book Value$2.02 per share Price / Book0.34Miscellaneous Outstanding Shares55,911,000Free Float52,054,000Market Cap$38.13 million OptionableOptionable Beta0.23 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:SPRO) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.